Pilgrim's Pride is sweetening its takeover offer for Hillshire Brands. CNBC's Jim Cramer and David Faber discuss the "insane" bidding for Hillshire.
CNBC's Jon Fortt and Liz Gannes, Re/code senior editor, discuss what Jimmy Iovine brings to Apple and if music is really that important to the tech giant's future.
Toni Sacconaghi, Sanford C. Bernstein senior research analyst, discusses what the Beats deal means for Apple and if this was the best decision for the tech giant to invest its capital.
"Squawk Box" host Andrew Ross Sorkin has the latest details on Pilgrim's Pride's bid for Hillshire Brands.
The sale of the 49-year-old restaurant chain is expected to close in July. TGI Fridays employs over 70,000 people globally.
YouTube is reportedly ready to make its largest acquisition ever. CNBC's Josh Lipton provides insight to the potential deal.
As AstraZeneca's shares slid following its rejection of Pfizer's new bid, the company's chairman said he was "reasonably confident" it was the right decision.
Max Wolff, Citizen V.C. chief economist; Yukari Kane, author of "Haunted Empire: Apple After Steve Jobs"; and David Nelson, Belpointe Asset Management.
A look at Apple's could-be deal with Beats Electronics, with CNBC's Morgan Brennan.
CNBC's Robert Frank reports on the race to be hip hop's first billionaire.
Discussing competition in the music streaming space, and what a potential deal between Apple and Beats Electronics could mean for the industry, with Elias Roman, Songza co-founder & CEO.
CNBC has learned Apple is in talks to buy headphone maker Beats Electronics for $3.2 billion. CNBC contributor Natalie Morris, and Peter Kafka, Re/code senior editor, discuss.
It's a huge departure for Tim Cook, says Matthew Garrahan, Financial Times media editor, discussing Apple's rumored attempt to acquire Beat Electronics for $3.2 billion.
Employees at Pfizer Inc's U.S. research centers may want to dust off their resumes if the company's proposed acquisition of Britain's AstraZeneca comes to fruition.
Nicholas Heyman, William Blair, discusses General Electric's possible acquisition of French train and power plant builder Alstom for more than $13 billion.
Sandy Villere, Villere Funds, shares his thoughts on Greenlight Capital's new stake in Conn's.
Eli Lilly Chairman & CEO John Lechleiter discusses his business' expansion of its animal health unit with the acquisition of Novartis' animal health business.
GlaxoSmithKline CEO Sir Andrew Witty, explains the large portfolio of vaccinations his company provides, and the value added from the company's acquisition of Novartis' vaccination business.
GlaxoSmithKline CEO Sir Andrew Witty, discusses the benefit to shareholders from his company's acquisition of Novartis' vaccination business, as well as its oncology unit.
Bob Moritz, PricewaterhouseCoopers chairman and senior partner, discusses the company's plan to boost its consulting business by extending its global reach.